Supply of the product Ipratropium Bromide by Boehringer Ingelheim

Overview

The Therapeutic Goods Act 1989 was enacted to provide for the regulation of therapeutic goods, including medicines, medical devices, and blood and blood components, to ensure their safety, quality, and efficacy. The Act was introduced to address the need for a comprehensive legislative framework governing the supply, advertising, and importation of therapeutic goods in Australia. The policy objective of the Act is to protect public health by ensuring that therapeutic goods available in Australia meet acceptable standards of quality and performance. The Therapeutic Goods Act 1989 is administered by the Therapeutic Goods Administration (TGA), an agency of the Australian Government's Department of Health. In this instance, the TGA has granted consent for the supply of ipratropium bromide (Atrovent) 250 micrograms/mL inhalation bottles, notwithstanding that the product does not conform to certain labelling requirements specified in TGO 69. This consent is subject to specific conditions, including the provision of relevant information in the Consumer Medicine Information (CMI) and Product Information (PI) documents, and applies only to the specified batch numbers.

Scope and Application

The Therapeutic Goods Act 1989 governs the regulation of therapeutic goods in Australia, encompassing a broad range of products such as medicines, medical devices, blood, tissues, and cosmetics. This Act applies to any person or entity involved in the manufacture, supply, import, export, or advertising of these goods within Australia. The Act’s jurisdiction extends across the Commonwealth, and it applies uniformly throughout all states and territories. However, certain exclusions and exemptions are specified within the Act and its subordinate instruments. For instance, some products may be exempt from certain regulatory requirements if they are intended for personal use or research purposes. The Act also includes provisions for the establishment of therapeutic goods regulations and standards through subordinate legislation, which can further extend or restrict its application. This comprehensive legislative framework ensures that therapeutic goods available in Australia meet safety, quality, and efficacy standards, thereby protecting public health.

Key Provisions

The Therapeutic Goods Act 1989 (the Act) governs the regulation of therapeutic goods in Australia. Section 14 of the Act allows for the delegate of the Secretary of the Department of Health to give consent for the supply of therapeutic goods that do not fully comply with certain regulatory standards, provided that certain conditions are met. In this instance, section 14(1) has been applied to allow for the supply of ipratropium bromide (ATROVENT) 250 micrograms/mL inhalation bottle [Aust R 39953], supplied by Boehringer Ingelheim, which does not conform with paragraph 3(9) of Therapeutic Goods Order (TGO) 69. This is because the antimicrobial preservative is not stated on the product labels, as required by that provision. This consent is subject to conditions outlined in section 15(1) of the Act, which applies to specific batch numbers (132431D and 231704E) and requires that the relevant information be included in the Consumer Medicine Information (CMI) and Product Information (PI) documents. No other changes have been made to the product. Under the Act, the Therapeutic Goods Administration (TGA) has the responsibility to ensure that therapeutic goods supplied in Australia meet acceptable standards of quality, safety, and efficacy. The obligations imposed on the parties involved in this consent include ensuring that the conditions outlined in section 15(1) are adhered to, specifically that the relevant information about the antimicrobial preservative is included in the CMI and PI documents for the specified batch numbers. Boehringer Ingelheim must also ensure that the product is supplied in accordance with the terms of this consent and that all required information is accurately and completely disclosed. Failure to comply with the conditions set out in the consent or with the requirements of the Act may result in legal consequences. Section 34 of the Act outlines various offences that can be committed if the provisions of the Act are breached, such as supplying therapeutic goods that do not comply with the standards set out in the Act or providing false or misleading information. The penalties for these offences can include fines and, in some cases, imprisonment. The maximum penalties for offences under the Act are specified in the Crimes Act 1914 and can vary depending on the nature and seriousness of the offence. For example, supplying therapeutic goods that do not comply with the standards set out in the Act can result in a fine of up to $220,000 for an individual or $1,100,000 for a body corporate, or imprisonment for up to five years, or both. It is essential for all parties involved to understand and comply with the obligations and potential consequences outlined in the Act to avoid any legal repercussions.